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2Endovascular Treatment of Resistant
and Uncontrolled Hypertension
Therapies on the Horizon
The treatment of resistant hypertension has undergone remarkable advancements in recent years. Endovascular radio
frequency renal sympathetic denervation (RSD) has shown initial success in treating resistant hypertension by targeting
the connection between the brain and renal sympathetic nerves. However, the encouraging results of ﬁrst-generation
RSD have been tempered by important procedural limitations and a need for long-term results of safety and efﬁcacy. In
an effort to build on early clinical success, several second-generation RSD technologies are now being developed that
may improve procedural safety and efﬁcacy. Preliminary evidence for some of the latest technologies is now available. In this
review, we summarize the current evidence in support of RSD and consider unique features of several new technologies that
are likely to reﬁne the endovascular treatment of resistant hypertension. (J Am Coll Cardiol Intv 2013;6:1–9) © 2013 by the
American College of Cardiology FoundationA
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cAmong the estimated 76 million Americans with hyperten-
sion, over one-half have inadequately controlled blood
pressure (BP) (1). This looming problem persists despite
national public health efforts promoting awareness and
achieving improved treatment rates (1). Over the past
decade, new therapeutic options for uncontrolled and resis-
tant hypertension (RH) that target the autonomic nervous
system have become the focus of considerable medical
interest. Renal sympathetic denervation (RSD) has stood
out as an intriguing and potentially viable treatment option
for RH, as was expertly reviewed in a previous issue of
JACC: Cardiovascular Interventions (2). However, important
limitations with available RSD treatments have provided an
opportunity for novel technologies to improve on already
impressive BP-lowering results.
Here we briefly review the societal impact of RH,
elaborate on the evolution of treatment favoring use of
autonomic modulation for RH, and explore various endo-
vascular strategies that may strengthen therapeutic options
against RH.
Scope of Resistant Hypertension
Resistant hypertension is defined as persistent elevation of
BP above goal despite concurrent use of 3 antihypertensive
agents, each of unique class with a diuretic included among
the treatment regimen, and with all drugs at target dose (3).
Hypertension that is controlled to goal levels using 4 or
more medications is also considered resistant to treatment
(3). From the 2003 to 2008 National Health and Nutrition
Examination survey cycles, 12.8% of the U.S. adult hyper-
tensive population met the strict definition for RH (4).
Even though RH accounts for a minor proportion of the
overall hypertensive population, it serves as an alarming marker sof increasingly more difficult BP control (5). Among adult
Americans taking at least 3 medications, the rate of uncon-
trolled hypertension has risen from 15.9% (1988 to 1994) to
28.0% (2005 to 2008) (6), mirroring the rising prevalence of
obesity from 23% (1988 to 1994) to 34% (2007 to 2008) (7).
s the epidemic of obesity and diabetes grows, the prevalence
f RH, and its associated costs are sure to rise. Whereas
ost-effectiveness and durability of new RH therapies has yet to
e determined, the concept of successful BP reduction among
igh-risk populations has garnered considerable enthusiasm
or patients and providers.
planchnicectomy and the Basis for
enal Sympathetic Denervation
The basis for targeting the autonomic nervous system to
treat RH was established decades ago. In 1938, hyperten-
sion had a 25% prevalence among Americans and carried a
clear association with cardiovascular disease (8). Treatment
was limited to a small number of sedative and antihyper-
tensive drugs and radical surgeries, such as nephrectomy and
surgical lysis of the autonomic nerves. Thoracolumbar
splanchnicectomy was introduced as a treatment for hyper-
tension, a particularly invasive surgical procedure involving
resection of splanchnic innervation to the kidneys (9). The
benefits of splanchnicectomy were confirmed in a large
nonrandomized clinical trial that spanned nearly a decade from
1938 to 1947. The dramatic results of surgery were clear; for
those treated surgically (n 1,266) versus those declined for
surgery and treated medically (n  467), 5-year mortality
ates were 19% and 54%, respectively (9). Furthermore, the
P-lowering result after surgery was durable. After a suc-
essful operation, some patients enjoyed BP-lowering re-
ults that extended up to 10 years or more. Nevertheless, as
T
e
p
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3medical treatments became increasingly available and effec-
tive, adverse surgical side effects and procedural risks rele-
gated surgical splanchnicectomy out of favor.
Over the next 50 years, considerable research efforts
contributed to a more refined understanding of the benefits
of autonomic renal nerve modification. The kidneys are
richly innervated with post-ganglionic sympathetic efferent
fibers that associate with efferent and afferent renal arteri-
oles, the juxtaglomerular apparatus, and the renal tubular
system (10). Acute increase in efferent sympathetic nerve
activity from the brain to the kidney results in renal vasocon-
striction, renin release, and sodium retention (Fig. 1). When
unchecked, excessive renal sympathetic efferent tone from the
brain contributes to pathological hypertension through these
mechanisms (Fig. 2) (11).
With recent advancements in technology, the concept of
severing the brain-kidney connection to treat poorly con-
trolled hypertension has undergone a revival. RSD targets
the renal efferent and afferent sympathetic nerves, which lie
in the adventitia of the arterial wall and are locally injured
Figure 1. Pathways of Sympathetic Activity Leading to Hypertension
1  increased; 2  decreased; CHF  chronic heart failure; LVH  left
ventricular hypertrophy; PVR  peripheral vascular resistance; RAAS p
renin-angiotensin-aldosterone system.during the procedure, thereby reducing brain-kidney crosstalk
and systolic BP. RSD has evolved into 3 unique strategies:
radiofrequency ablation (RFA); ultrasonic ablation; and tissue-
directed pharmacological ablation (Table 1). Most RSD tech-
nologies have been investigated among the RH population,
although contemporary clinical studies have expanded applica-
tion to a population with less-severe BP elevation that does not
meet the strict definition of RH. Emerging preliminary results
from small clinical trials provide encouraging signs that RSD
for RH is rapidly advancing.
Radiofrequency Ablation Technology
The feasibility of RFA for the renal nerves using a standard
electrophysiology catheter has been applied and proven
successful (12). However, proprietary systems specifically
designed for RSD are most likely to maximize patient
comfort, procedural safety, and efficacy, if not at greater
costs. Several variations of RFA technology designed for
RSD are under clinical study or are in development.
Symplicity renal denervation
system. The Symplicity catheter
system (Medtronic Inc., Minne-
apolis, Minnesota) uses a novel
percutaneous single-electrode RFA
catheter inserted sequentially into
each renal artery that delivers abla-
tive energy to the endoluminal sur-
face. The Symplicity catheter sys-
tem received CE (Conformité
Européene) Mark approval in Eu-
rope (2010), although it remains
investigational in the United States.
The SYMPLICITY HTN-3 (Re-
nal Denervation in Patients With
Uncontrolled Hypertension) trial is currently under way and
will be pivotal for potential U.S. Food and Drug Administra-
tion approval of the device.
The SYMPLICITY HTN-1 (SYMPLICITY I: One-
Year Results Following Sympathetic Renal Denervation in
Refractory Hypertension) (13) and SYMPLICITY HTN-2
(Renal Sympathetic Denervation in Patients With
Treatment-Resistant Hypertension) (14) clinical trials eval-
uated the safety and effectiveness of RSD among an inter-
national cohort of patients with RH. The SYMPLICITY
HTN-1 trial was a proof-of-principle, open-label, multi-
center study of procedural safety and efficacy for RSD
among patients with RH (13). The SYMPLICITY HTN-2
trial was a larger, randomized, efficacy study that built on
the impressive results from SYMPLICITY HTN-1 (14).
he results of these trials have been extensively reviewed
lsewhere (2,15–18) and are summarized in Table 2. Im-
ortant limitations of the Symplicity catheter system have
Abbreviations
and Acronyms
BP  blood pressure
CE  Conformité Européene
EuroPCR  European
Association for
Percutaneous Cardiovascular
Interventions
RFA  radiofrequency
ablation
RH  resistant hypertension
RSD  renal sympathetic
denervationrovided opportunities for further improvement of RSD
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4application. These opportunities now drive emerging tech-
nologies focused on advancing the application of RSD.
Limitations of the SYMPLICITY HTN-1 and HTN-2 trials. Al-
though the Symplicity catheter system has proven itself as
an acceptably safe and effective treatment for RH, several
aspects of the RSD procedure are likely to undergo optimi-
zation in the near future. Reducing procedural duration and
exposure to painful endovascular RFA is a priority. Smaller
delivery systems might expand application to a broader
spectrum of patients; currently, the Symplicity catheter is
not recommended for renal arteries 4 mm in diameter or
those with 20 mm of longitudinal endoluminal surface
accessible for ablation. Mapping of pre- and post-
procedural renal nerve activity may provide confirmation of
procedural success, thereby enhancing effectiveness and
durability of RSD.
Periprocedural sedation is required for diffuse, visceral,
nonradiating abdominal pain during denervation. The Sym-
plicity procedure involves a series of 2-min ablations along
the endoluminal surface of the artery (19). The initial
procedure time reported in the SYMPLICITY HTN-1 trial
was estimated at 40 min, although as experience has grown,
Figure 2. Proposed Pathways of Therapeutic Benefit of RSD
HR  heart rate; other abbreviations as in Figure 1.procedural time continues to shrink. Reducing proceduraltime and exposure to painful ablation has been an important
advance in newer technologies.
The Symplicity catheter system requires femoral arterial
access to place a guiding catheter in the renal arteries
through which the Symplicity catheter is advanced. In the
SYMPLICITY HTN-1 trial, a single patient suffered renal
artery dissection due to manipulation of the guiding cathe-
ter. Another patient developed a femoral pseudoaneurysm.
From the SYMPLICITY HTN-2 trial, procedure-related
adverse events included a single femoral artery pseudoaneu-
rysm. Radial arterial access has become increasing popular
for endovascular procedures owing to reduced rates of
vascular complications. Radial access RSD may also facili-
tate cannulation of the renal arteries and improve procedural
safety. Further advancements that might eliminate the need
for a guiding catheter, which can have more aggressive
angulations than the treatment catheter itself, might reduce
procedure-related renal artery dissection.
Other acute, procedural complications that have been
reported include intraprocedural bradycardia requiring atro-
pine and post-procedural hypotension. Whereas these dra-
matic consequences of RSD likely indicate the abrupt effect
of the procedure, the ablation of renal nerves might be best
tolerated with a graded, gradual ablative effect. New tech-
nologies that provide biochemical ablation might enable
such a strategy.
The short-term BP-lowering results from SYMPLICITY
HTN-1 and HTN-2 are encouraging, although further
evidence is needed to confirm the durability and long-term
effectiveness of RSD. Among a small cohort of nonrandom-
ized patients in the original SYMPLICITY HTN-1 cohort,
2- and 3-year results suggest the technology offers durable
BP-lowering. Mean reduction in office-based BP at 2 years
(n  18) was 32/14 mm Hg (20) and at 3 years (n  24)
was 33/19 mm Hg (21). Nevertheless, 13% of SYM-
PLICITY HTN-1 patients had systolic BP reductions
10 mm Hg and were deemed nonresponders (13).
Similarly, 10% of intervention patients had no decline in
systolic BP in the SYMPLICITY HTN-2 trial (14). The
ability to measure procedural success, perhaps via renal
nerve monitoring, might enable identification of nonre-
sponders to RSD. Such an alert might enable additional
treatment acutely, or suggest alternative modalities to
treat RH. Treatment of RH is likely to be advanced by
further research that elaborates on appropriate patient
selection and post-procedural indicators of efficacy.
EnligHTN multielectrode renal denervation system. The
multielectrode basket design of the EnligHTN catheter (St.
Jude Medical Inc., St. Paul, Minnesota) allows for simulta-
neous energy delivery to 4 sites along the endoluminal
surface of the artery, with a potential benefit of reducing
renal denervation procedural time. Shorter treatment time
offers less RFA time and thereby reduced procedural pain
for the patient, a known and common side effect of RSD as
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5described in the SYMPLICITY trials. The EnligHTN
RFA catheter system recently received CE Mark approval
(May 2012) on the basis of preliminary results of St. Jude’s
ongoing ARSENAL (Safety and Efficacy Study of Renal
Artery Ablation in Resistant Hypertension Patients) trial.
This prospective, open-label, feasibility study began enroll-
ing in October 2011 at centers in Greece and Australia.
Study completion is anticipated in March 2013 after enroll-
ment and 6-month follow-up of 47 participants. Primary
outcome measures are all adverse events and office-based BP.
Exclusion criteria are similar to that of the SYMPLICITY
trials. Preliminary results presented at the 2012 European
Association for Percutaneous Cardiovascular Interventions
Table 1. Overview of Clinical Trials Enrolling Hypertensive Patients for End
Product Name Product Design Clinical Trial N
Radiofrequency ablation
Symplicity RFA catheter Single-electrode RFA catheter SYMPLICITY HTN-1
SYMPLICITY HTN-2
SYMPLICITY HTN-3
Effect of renal dene
biological variabl
Renal nerve ablation
patients
PRAGUE-15
Renal denervation in
with RH and OSA
EnligHTN RFA catheter Multielectrode RFA catheter ARSENAL
Vessix V2 RFA catheter Balloon-mounted RFA catheter REDUCE-HTN
OneShot RFA catheter Irrigated, balloon-mounted RFA
catheter
RAPID
ThermoCool
cryoablative catheter
Irrigated RFA catheter SWAN HT
SAVE
RELIEF
Chilli II cryoablative
catheter
Irrigated RFA catheter SAVE
Ultrasonic ablation
PARADISE ultrasonic
catheter
Ultrasonic balloon catheter REALISE
TIVUS ultrasonic
catheter
Ultrasonic autoregulating
balloon catheter
In development
Kona medical ultrasonic
system
Low-intensity external ultrasonic
ablation system
In development
Tissue-directed pharmacological ablation
Bullfrog microinfusion
catheter
Microneedle-equipped balloon
catheter
In development
ARSENAL Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients tri
Percutaneous Renal Denervation System catheter; PRAGUE-15  Renal Denervation in Refracto
REDUCE-HTN  Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Trans
Hypertension trial; REALISE Renal Denervation byUltrasound Transcatheter Emission trial; RFA r
Chronic Hypertension study; SWAN HT Renal Sympathetic Modification in Patients With Essentia
Denervation in Refractory Hypertension trial; SYMPLICITYHTN-2 Renal Sympathetic Denervation i
With Uncontrolled Hypertension trial; TIVUS therapeutic intravascular ultrasound.(EuroPCR) meeting included 1-month mean office BPchange of 28/10 mm Hg from baseline, with 78% of
patients having systolic BP reduction of 10 mm Hg (22).
No serious complications were reported. Minor complica-
tions that were reported included procedure-related access
site hematomas (n  4), vasovagal responses with sheath
emoval (n  3), and post-procedural bradycardia (n  2).
Vessix V2 renal denervation system. The Vessix V2 renal
denervation system (Vessix Vascular Inc., Laguna Hills,
California) offers a unique, over-the-wire low-pressure bal-
loon equipped with bipolar RFA electrodes attached to the
balloon surface that is claimed to offer treatment times of
30 s. The balloon catheter also accommodates smaller
arterial diameters (3.0 mm). The Vessix V2 balloon catheter
ular Renal Nerve Ablation
Hypertension Type
Studied Trial Status
Clinical
Trial ID Sponsor
Resistant Active, not
recruiting
NCT00664638 Medtronic Inc.
Resistant Active, not
recruiting
NCT00888433
Resistant Recruiting NCT01418261
on Resistant Recruiting NCT01427049
D Resistant, with Stage
3–5 CKD
Recruiting NCT01442883
Uncontrolled Recruiting NCT01560312
nts Uncontrolled, with
OSA
Recruiting NCT01366625
Resistant Active, not
recruiting
NCT01438229 St. Jude, Inc.
Resistant Recruiting NCT01541865 Vessix Vascular Inc.
Resistant Recruiting NCT01520506 Maya Medical Inc.
Uncontrolled Recruiting NCT01417221 Biosense Webster Inc.
Uncontrolled Recruiting NCT01628198
Uncontrolled Recruiting NCT01628172
Uncontrolled Recruiting NCT01628198 Boston Scientiﬁc Inc.
Resistant Recruiting NCT01529372 ReCor Medical Inc.
Cardiosonic Ltd.
Kona Medical Inc.
Mercator MedSystems
Inc.
chronic kidney disease; HTN hypertension; OSA obstructive sleep apnea; PARADISE ReCor
ertension trial; RAPID  Rapid Renal Sympathetic Denervation for Resistant Hypertension trial;
l Angioplasty Catheter; RELIEF  Renal Sympathetic Denervation for the Management of Chronic
quency ablation; RH resistant hypertension; SAVE Impact of Renal Sympathetic Denervation on
tension study; SYMPLICITY HTN-1 SYMPLICITY I: One-Year Results Following Sympathetic Renal
tsWith Treatment-Resistant Hypertension trial; SYMPLICITYHTN-3 Renal Denervation in Patientsovasc
ame
rvation
es
in CK
patie
al; CKD
ry Hyp
lumina
adiofre
l Hyper
n Patiensystem is currently being studied in the REDUCE-HTN
bR
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N
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i
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6(Treatment of Resistant Hypertension Using a Radiofre-
quency Percutaneous Transluminal Angioplasty Catheter)
study. REDUCE-HTN is an ongoing prospective, open-
label, feasibility study that began enrollment in February
2012 throughout centers in Europe and Australia. Enroll-
ment is estimated at 64 participants with study completion
anticipated in August 2014. The primary outcome is acute
procedural safety. Secondary efficacy outcomes of
6-month office-based and 24-h ambulatory BP assess-
ment will also be performed. Preliminary results of
Table 2. Summary of the SYMPLICITY HTN-1 and SYMPLICITY HTN-2 Trials
SYMPLICITY HTN-1 (13)
Study characteristics
Study design ● Nonrandomized, cohort, unblinded to treatment
Enrollment period ● June 2007 to November 2008
Patient population ● 45 subjects*
● Mean age: 58  9 yrs; 96% white, 44% women, 31% d
● Mean BP (mm Hg) at enrollment: 177/101 (SD 20/15)
Inclusion criteria ● Ofﬁce-based SBP 160 mm Hg, on 3 antihypertensiv
medications, including a diuretic or drug intolerance
Exclusion criteria ● Known secondary cause of hypertension (except OSA o
● Type I diabetes mellitus
● Pregnancy
● Signiﬁcant valvular heart disease
● Existing PPM or ICD
● Use of clonidine, moxonidine, rilmenidine, or warfarin
● Renovascular abnormalities†
● CKD with eGFR 45 ml/min/1.73 m2
Outcomes
Primary ● Acute procedural and long-term safety
● Mean reduction in ofﬁce-based SBP at 12 months
Results
Primary efﬁcacy
outcomes
Follow-up
period,
month(s)
Subjects available
for follow-up
analysis, n (%),
N  45
Mean change in o
based BP
SBP/DBP
(mm Hg)
9
1 41 (91) 14/10
3 39 (87) 21/10
6 26 (58) 22/11
9 20 (44) 24/11
12 9 (20) 27/17
Periprocedural safety
outcomes
● Renal artery dissection (n  1)
● Pseudoaneurysm at femoral artery access site (n  1)
● No long-term vascular complications observed with
procedure imaging studies (n  18 had repeat renal
angiograms 30 days after treatment; n  14 had MR
n  17 had CTA within 6 months after treatment)
Nonresponders ● 6 of 45 (13%) had SBP reductions 10 mm Hg
*Number of subjects that received treatment and included in study analysis; all subjects18 years
artery stenosis, prior renal artery angioplasty, or dual renal arterial supply per kidney. Renal arterym
for ablation. ‡Three patients lost to follow-up at 6 months in each group.
BP blood pressure; CI confidence interval; CVA cerebrovascular accident; DBP diastolic
MImyocardial infarction; MRImagnetic resonance imaging; PPM permanent pacemaker; SBREDUCE-HTN were presented at EuroPCR 2012. In e10 patients, the mean office-based BP was 30/11 mm Hg
elow baseline BP (23).
OneShot renal denervation system. The RAPID (Rapid
enal Sympathetic Denervation for Resistant Hyperten-
ion) trial is a prospective, open-label, feasibility study that
egan enrollment in May 2012 throughout Europe and
ew Zealand. The OneShot catheter (Maya Medical Inc.,
ampbell, California) was unveiled at EuroPCR 2012 and
ses an irrigated balloon catheter with a helical electrode on
ts surface, allowing a single-treatment approach. Estimated
SYMPLICITY HTN-2 (14)
● Randomized control, unblinded to treatment
● June 2009 to January 2010
● 106 subjects (52 treated, 54 control)*
● Mean age: 58  12 yrs; 97% white, 42% women, 67% diabetic
● Mean BP (mm Hg) at enrollment: treatment group: 178/97 (SD 18/16);
control group: 178/98 (SD 16/17)
● Ofﬁce-based SBP  160 mm Hg (or diabetics with SBP 150 mm Hg), on 3
antihypertensive medications, including a diuretic or drug intolerance
) ● Type I diabetes mellitus
● Pregnancy
● Signiﬁcant valvular heart disease
● Existing PPM or ICD
● Use of clonidine, moxonidine, rilmenidine, or warfarin
● Renovascular abnormalities†
● CKD with eGFR 45 ml/min/1.73 m2
● Contraindications to MRI
● History of recent MI, USA, or CVA within 6 months of enrollment
● Between-group difference in ofﬁce-based mean SBP at 6 months
Follow-up
period,
month(s)
Mean change in BP
SBP/DBP
(mm Hg)
Follow-up
period,
month(s)
Mean change in
BP SBP/DBP
(mm Hg)
1 20/7 1 0/0
3 24/8 3 4/2
6 32/12 (SD 23/11) 6 1/0 (SD 21/10)
Denervation group (N  49)‡ Control group (N  51)‡
● 7 of 52 (13%) required atropine for intraprocedural bradycardia
● Among treated subjects: TIA (n  1), angina requiring coronary stent (n  1),
hypotension (n  1), hypertensive crisis (n  1), hospital admission for nausea
and vomiting “possibly related to hypertension” (n  1)
● Among control subjects, TIA (n  2), angina requiring coronary stent
(n  1)
● 5 of 49 (10%) treated subjects and 24 of 51 (47%) control subjects had no
decline in SBP
● 4 of 49 (8%) treated subjects and 6 of 51 (12%) control subjects had drug
increases before 6-month follow-up
ere referred to centers of hypertension specialty care. †Renovascular abnormalities included renal
t least 4mm in diameter and have at least 20mmof longitudinal renal arterial dimension accessible
ressure; eGFR estimated glomerular filtration rate; ICD implantable cardioverter-defibrillator;
tolic blood pressure; USA unstable angina; other abbreviations as in Table 1.iabetic
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r CKD
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5% CI
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7BP160 mm Hg, although it requires a specific renal artery
diameter of 4 to 7 mm and a segment amendable to ablate
of 20 mm. The primary outcome is chronic procedural
safety and office-based systolic BP reduction10 mm Hg at
6 months compared with baseline. Study completion is
anticipated December 2013. The OneShot technology re-
ceived CE Mark approval in February 2012.
ThermoCool renal sympathetic denervation system. The
elsius ThermoCool RFA catheter system (Biosense Web-
ter Inc., Diamond Bar, California) uses a saline-irrigated
atheter to ablate the endoluminal surface of the renal
rtery. The SWAN HT (Renal Sympathetic Modification
n Patients With Essential Hypertension) study is an
ngoing, prospective, nonrandomized, open-label, safety
nd efficacy trial evaluating the ThermoCool catheter in
atients with essential hypertension (140/90 mm Hg).
he study began enrollment in August 2011, has an
nticipated enrollment of 800 patients, and a study comple-
ion date of August 2016. Results of a small pilot study
sing the same catheter in 10 patients with uncontrolled
ypertension was recently published, demonstrating im-
rovement in blood pressure while reducing markers of
ympathetic activity (24).
In a separate study, the Celsius ThermoCool RFA
atheter and the Chilli II irrigated RFA catheter (Boston
cientific Inc., San Jose, California) are being evaluated in
he long-term safety and efficacy SAVE (Impact of Renal
ympathetic Denervation on Chronic Hypertension) study.
nrollment began in May 2012. The study is planned to
nclude 500 patients with BP 140/90 mm Hg with an
nticipated study completion of December 2019. The pri-
ary outcome is change in ambulatory BP at 6 months,
hich is unique from many other renal denervation studies
hat use office-based measures. Secondary outcome mea-
ures are planned through 48 months and include office-
ased BP, renal artery blood flow and dimension, renal
unction, and difference in number of total antihypertensive
edications.
Despite its limitations, RFA of the renal sympathetic
erves currently leads the available technologies for the
ndovascular treatment of RH. As alternatives to painful
FA, ultrasonic and tissue-directed pharmacological RSD
ave been introduced with early but intriguing BP-lowering
esults that deserve consideration.
ltrasonic Ablation Technology
Ultrasound-based RFA may play a role in sympathetic
denervation, offering a more targeted injury pattern to the
renal sympathetic nerves contained within the adventitia of
the renal artery. A number of companies are pursing
ultrasound ablative technology with various invasive ap-
proaches as well as a unique noninvasive system.PARADISE catheter system. The PARADISE (ReCor Per-
cutaneous Renal Denervation System) catheter (ReCor
Medical Inc., Ronkonkoma, New York) uses a 6-F ultra-
sonic balloon catheter and self-centering transducer that
delivers a proprietary energy algorithm to circumferentially
ablate the renal sympathetic nerves. The ultrasonic sound
waves emitted from the central core of the balloon produce
frictional heating of soft tissues outside of the artery while
the fluid-filled balloon cools the endoluminal surface of the
artery. The REALISE (Renal Denervation by Ultrasound
Transcatheter Emission) study is a single-arm, open-label,
first-in-man feasibility study of the PARADISE catheter in
20 RH patients with a primary outcome of acute procedural
safety. Secondary outcomes include 12-month change am-
bulatory BP and 12-month change in baseline antihyper-
tensive medication intake. Preliminary data from 15 pa-
tients was presented at EuroPCR 2012, demonstrating
office-based BP was reduced by an average of32/16 mm Hg
ver a 3-month follow-up (25).
Therapeutic intravascular ultrasound catheter system. The
herapeutic intravascular ultrasound (TIVUS) system was
eveloped as a high-intensity, nonfocused catheter-based
blation system (Cardiosonic Ltd., Tel Aviv, Israel). The
IVUS catheter is delivered into the renal artery over a
.014-inch guidewire via a 6-F flexible sheath. The RFA
ource does not contact the arterial wall, enabling remote
hermal energy delivery to the adventitia while sparing the
ndoluminal surface. The technology offers self-regulating
afety technology that monitors local tissue temperature that
revents overtreatment if blood temperature becomes
levated.
Ultrasound-based treatment for hypertension. Kona Medi-
cal Inc. (Bellevue, Washington) is developing a noninvasive
technology using low-intensity focused ultrasound that
avoids many of the challenges of invasive endovascular
intervention. The system is integrated with an external
imaging-modality that identifies and monitors the treat-
ment areas while delivering low-intensity ultrasonic energy
with an external ultrasound probe. This system is in the
pre-clinical phase of development. Given a noninvasive
approach, if the Kona system proves successful, it is sure to
generate considerable medical interest.
Tissue-Directed Pharmacological
Ablation Technology
An alternate approach to induce renal sympathetic nerve
injury may be achieved through the delivery of neurotoxins.
Vincristine is a vinca alkaloid antineoplastic drug mainly
used to treat acute leukemia, lymphomas, and some sarco-
mas. Vincristine also exhibits neurotoxic properties that may
make the drug suitable for RSD using microinfusion cath-
eter technology (26). In a swine model, successful sympa-
thetic renal denervation using vincristine and the Bullfrog
s
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8microcatheter was presented at the 2011 meeting of Trans-
catheter Therapeutics in San Francisco (27).
Bullfrog microinfusion catheters. The Bullfrog microinfu-
ion catheter (Mercator MedSystems Inc., San Leandro,
alifornia) was designed to inject therapeutic agents directly
hrough the arterial wall and into the perivascular tissues.
or renal denervation, the sympatholytic neurotoxin
uanethidine has been studied for injection in the renal
rteries. The U.S. Food and Drug Administration approved
uanethidine in 1960 for the treatment of moderate-to-
evere hypertension. When taken orally, guanethidine ac-
umulates in low concentrations in the sympathetic nerves
nd reversibly interferes with the transmission of neural
ormones, thereby decreasing BP. Given locally, guanethi-
ine induces an autonomic denervation directly and through
n immune-mediated pathway (28).
The Bullfrog catheter is equipped with a 130-m mi-
croneedle and protective balloon system. The balloon cath-
eter is guided and inflated at low expansion pressures
(approximately 2 atm) within the renal artery to deploy the
neurotoxin. As the balloon is inflated, the needle becomes
unsheathed from the balloon and penetrates the vessel wall,
allowing for perivascular delivery of the therapeutic agent.
The Bullfrog catheter has U.S. Food and Drug Adminis-
tration 510(k) clearance for medication delivery to the vessel
wall and perivascular area.
Other Nonendovascular Autonomic
Modulation Therapies
Baroreceptor activation therapy, spinal cord stimulation,
and vagal-nerve stimulation represent novel and nonendo-
vascular treatments against RH (29–31) and other sympa-
thetically driven conditions, such as chronic heart failure,
among others. Though beyond of the scope of this review,
these nonendovascular therapies may complement or sup-
plant some of the RSD therapies described herein. Because
these non-RSD treatments generally require more invasive,
elaborate procedures, the aforementioned percutaneous op-
tions may have more long-term appeal.
Conclusions
The results of SYMPLICITY HTN-3, ARSENAL, and
other pivotal trials are sure to expand the possibilities for
endovascular treatment of RH. Whereas emerging evidence
from these small trials are encouraging, results from larger
randomized clinical trials are needed to confirm procedural
safety and durability before more widespread clinical appli-
cation occurs. Those at high risk for RH-related cardiovas-
cular complications are likely to gain the most from RSD,
particularly if a positive impact on important clinical out-
comes can be demonstrated. With further confirmatory
evidence of procedural safety, patient selection, and thera-peutic durability, RSD is sure to strengthen the treatment
options for poorly controlled hypertension.
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